Indivior Pharmaceuticals, Inc. Revenue 2022–2025
Indivior Pharmaceuticals, Inc. annual/quarterly revenue history and growth rate from 2022 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Indivior Pharmaceuticals, Inc. revenue for the quarter ending March 31, 2026 was 317.0 M, a 19.17% increase year-over-year.
- Indivior Pharmaceuticals, Inc. revenue for the twelve months ending March 31, 2026 was 1.2 B.
- Indivior Pharmaceuticals, Inc. annual revenue for 2025 was 1.2 B, a 4.29% increase from 2024.
- Indivior Pharmaceuticals, Inc. annual revenue for 2024 was 1.2 B, a 8.69% increase from 2023.
- Indivior Pharmaceuticals, Inc. annual revenue for 2023 was 1.1 B, a 21.31% increase from 2022.
- Indivior Pharmaceuticals, Inc. annual revenue for 2022 was 901.0 M.
Indivior Pharmaceuticals, Inc. (INDV) — Frequently Asked Questions
Indivior Pharmaceuticals, Inc. (INDV) is a publicly traded US company. It has a market capitalization of $4.93B. In fiscal 2025 it reported revenue of $1.24B and net income of $210M. Explore INDV's stock price, financial statements, earnings history, margins and key ratios below.
What is Indivior Pharmaceuticals, Inc.'s market cap?
Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.93B.
What is the INDV stock price?
INDV trades at $38.50 (+1.08% on the day).
How much revenue does Indivior Pharmaceuticals, Inc. make?
Indivior Pharmaceuticals, Inc. reported revenue of $1.24B in fiscal 2025.
Is INDV profitable?
In fiscal 2025, Indivior Pharmaceuticals, Inc. reported net income of $210M.
What is INDV's P/E ratio?
Based on diluted EPS, INDV has a price-to-earnings (P/E) ratio of about 23.5.